6 results about "Ischemic cardiomyopathy" patented technology

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The application discloses a method and application of knocking down ubiquitin-specific peptidase 7 protein, and belongs to the field of biological medicine. The method for knocking down the USP7 protein comprises: specifically inhibiting the expression of USP7 in endothelial cells through gene intervention, and the gene intervention means comprises shRNA, siRNA or recombinant virus carrier-mediated USP7 expression down-regulation. Further provided is a USP7 knockdown reagent for preparing a drug for treating endothelial cell inflammation or a cardiovascular disease, in particular, the USP7 knockdown reagent is a USP7 knockdown virus carrier containing a Cdh5 promoter; the cardiovascular disease comprises heart failure, myocardial infarction or ischemic cardiomyopathy. The application specifically knocks down the expression of USP7 in endothelial cells through gene intervention, significantly improves the migration, tube formation capacity and reduces the apoptosis of the endothelial cells, repairs endothelial dysfunction, the USP7 knockdown virus carrier is used for preparing a drug for treating a cardiovascular disease, and has important clinical value.

The invention belongs to the field of new application of medicines, and particularly relates to application of Oloinab in preparation of medicines for treating and / or preventing ischemic cardiomyopathy. Animal experiments prove that Oloinab can remarkably improve the left ventricular ejection fraction and the left ventricular short axis shortening rate of myocardial infarction model mice, improve the heart function and reduce the cardiac fibrosis area, and it is indicated that Oloinab has the effect of improving myocardial remodeling and systolic dysfunction. The discovery provides a new treatment strategy for ischemic cardiomyopathy, and has an important clinical application prospect.

The invention discloses application of sFRP2 in preparation of a medicine for treating ischemic heart failure by inhibiting a Wnt / beta-catenin signal channel, a related kit and a medicine screening method, relates to the technical field of biological medicines, and discloses application of sFRP2 in preparation of a medicine for treating heart failure caused by ischemic cardiomyopathy by inhibiting the Wnt / beta-catenin signal channel. The medicine comprises an effective dose of sFRP2 protein; the medicine is characterized by comprising a Wnt / beta-catenin signal channel inhibitor, the invention relates to a kit for evaluating the risk of ischemic heart failure. The kit comprises a reagent for detecting the expression level of sFRP2 and Wnt / beta-catenin; the invention relates to an application in a medicine for treating ischemic heart failure by inhibiting a Wnt / beta-catenin signal channel, a related kit and a medicine screening method, which are used for developing a new treatment medicine and improving the treatment effect of the ischemic heart failure. Meanwhile, the invention provides a kit for evaluating the risk of ischemic heart failure, and early and accurate diagnosis and risk evaluation of the disease are realized.

The invention discloses application of Auranofin in preparation of a medicine for preventing and / or treating ischemic cardiomyopathy and heart failure, and belongs to the field of biological medicine. In-vivo and in-vitro experiments prove that the Auranofin can remarkably improve cardiac function indexes after myocardial ischemia reperfusion injury, so that the Auranofin has a definite pharmacological action in the aspects of preventing and treating ischemic cardiomyopathy and heart failure, a new candidate scheme is provided for the drug treatment of the diseases, and the application of the Auranofin in the treatment of ischemic cardiomyopathy and heart failure is developed. Meanwhile, the application prospect of the Auranofin in the field of cardiovascular diseases is expanded, and the Auranofin has important theoretical value and clinical transformation potential.

The application relates to the field of biological medicine, and provides application of OpiCa1 mutant peptide DE-4A in antagonizing heart failure after myocardial infarction. Experiments prove that the polypeptide DE-4A can remodel myocardial calcium homeostasis by restoring RyR2 protein stability and blocking excessive activation of the CaMKII signal pathway. This mechanism effectively reduces myocardial injury and fibrosis, significantly improves ventricular remodeling and heart dysfunction after myocardial infarction, and provides new experimental evidence for the treatment of ischemic cardiomyopathy. DE-4A has the effects of improving myocardial contractile function, regulating Ca 2+ homeostasis, which may be a key link in the pharmacodynamic mechanism, and provides new experimental evidence for the treatment of ischemic heart disease.